SMARCA4 and neoplasm: The model developed here combines clinical variables available preoperatively (tumor morphologic appearance on CT, tumor SUVmax, and clinical stage) and genomic data (SMAD4 and SMARCA4 alterations) that can be obtained from a preoperative biopsy specimen to better guide the therapeutic strategy.